Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Diabetic Macular Edema
Biotech
Aviceda raises $207M for geographic atrophy drug's ph. 3 journey
Aviceda has secured $207.5 million in series C funds as the biotech awaits a readout this year for its lead eye disease drug.
James Waldron
Jan 7, 2025 9:38am
Merck has clear vision to eye disease assets with $3B EyeBio buy
May 29, 2024 8:32am
Rezolute’s oral Eylea rival hits phase 2 goal, sending stock up
May 22, 2024 7:15am
Oxurion fails phase 2 eye disease trial, plans bankruptcy filing
Nov 20, 2023 8:30am
Kodiak resurrects eye drug after ph. 3 data renew approval plans
Nov 6, 2023 8:40am
'Unexpected' cataracts in ph. 3 end Kodiak's hopes for eye drug
Jul 24, 2023 8:58am
